Bristol-Myers Squibb Q4 2025 Earnings Analysis

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode quarterly reports so you don't have to. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Bristol Myers Squibb's Q4 2025 earnings call - and let me tell you, this one was packed with updates.But first, Jordan, I need to get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And speaking of packed earnings calls, Bristol Myers definitely delivered on that front. Let's start with the headline numbers because they tell quite a story about this company's transformation.**ALEX**: Absolutely. So Q4 revenue came in flat year-over-year at about $12.5 billion, but here's the key detail that investors need to understand - their growth portfolio, which includes all their newer drugs, grew 15% in the quarter and represented nearly 60% of total revenue. That's a massive shift from where this company was just a few years ago.**JORDAN**: Right, and for the full year, that growth portfolio grew 17%. What's really impressive is that despite losing roughly $4 billion in revenue from legacy products - we're talking about patent cliffs and generic competition - the growth portfolio almost completely offset those declines. That's the kind of pipeline execution that pharma investors dream about.**ALEX**: Let's talk about some of those growth drivers. Reblozyl, their blood disorder treatment, crossed $2 billion in annual sales. Breyanzi, their CAR-T cell therapy, grew 47% in Q4. And then you have Camzyos for heart disease growing 57%. These aren't just incremental gains - these are blockbuster-level products hitting their stride.**JORDAN**: And here's what caught my attention from CEO Christopher Boerner's comments - he emphasized they're entering 2026 with "good momentum." But the real story is what's coming in the pipeline. They're expecting six registrational data readouts in the second half of 2026. That's potentially six new revenue streams or major label expansions.**ALEX**: Jordan, let's break down that pipeline because it spans multiple therapeutic areas. You've got Milvexian for atrial fibrillation and stroke prevention - that's a massive market where they're trying to compete with their own Eliquis. Then there's admilparent for lung fibrosis, and several multiple myeloma treatments. This isn't just one bet - it's a diversified portfolio of shots on goal.**JORDAN**: Speaking of Eliquis, that was probably the most complex part of the call. The drug is actually expected to grow 10-15% in 2026, which surprised me given it's facing patent cliffs. But management explained they took a strategic pricing reduction that eliminates certain penalty rebates while expanding patient access.**ALEX**: That's a fascinating strategy. CFO David Elkins explained that the roughly 40% price reduction actually helps them competitively because it removes inflationary penalties that had been building up over years. It's counterintuitive - lower prices leading to higher growth - but it makes sense when you understand the complex rebate structures in pharma.**JORDAN**: However, they're also guiding for a $1.5 to $2 billion step-down in Eliquis revenue from 2026 to 2027, primarily due to European patent expiries. So investors are looking at one good year before facing those headwinds.**ALEX**: Let's talk about their cost management because this is where Bristol Myers is really showing discipline. They delivered $1 billion in cost savings in 2025 and expect another billion over 2026-2027. But here's the smart part - they're reinvesting some of those savings into growth initiatives like their partnership with BioNTech on pemiglatinib.**JORDAN**: That partnership caughtThis episode includes AI-generated content.